期刊文献+

乳腺癌患者术后预后相关因素分析 被引量:2

Analyses of prognostic factors for breast cancer patients
下载PDF
导出
摘要 目的探讨影响乳腺癌患者术后预后的相关因素。方法对101例乳腺癌患者,进行回顾性研究。本组病例采用Log-rank单因素分析和COX多因素模型的分析方法分析乳腺癌预后的相关指标。结果Log-rank单因素分析结果提示肿瘤大小(直径>5cm)、病理分级、淋巴结转移、HER-2/neu和CD44五个因素是乳腺癌的预后因素(P均<0.05),ER和PR不能作为乳腺癌的预后指标;进一步采用COX多因素分析结果提示,仅有HER-2/neu、肿瘤大小、淋巴结转移和病理分级是乳腺癌预后的独立预测指标。结论肿瘤大小、病理分级、淋巴结转移、HER-2/neu是临床判断乳腺癌预后有价值的指标。 Objective To investigate breast cancer. Methods 101 cases with breast the influencing prognostic factors for the patients with cancer were analyzed retrospectively. The influencing prognostic factors for these patients were analyzed by Log-rank single factor analysis and Cox Multiple factors analysis. Results Log-rank single factor analysis results suggested that tumor size (diameter 〉 5 cm), pathological grading, lymph node metastasis, HER-2/neu and CD44 were five factors of breast cancer prognostic factors, ER and PR can not be used as breast cancer prognosis indexes; Cox Multiple factors analysis showed that HER-2/neu, tumor size,pathological grade, lymph node metastasis were independent predicted factors of breast cancer,but CD44 was not an independent prognostic index. Conclusion Tumor size, pathological grading, lymph node metastasis, HER-2/neu are the valuable clinical prognostic indicators of breast cancer.
出处 《岭南现代临床外科》 2008年第4期247-249,共3页 Lingnan Modern Clinics in Surgery
基金 广东省医学科研基金资助课题(A2005226) 广东省自然科学基金资助课题(7001592) 广东省科技计划资助课题(2006B36002010)
关键词 乳腺癌 预后 COX多因素分析 Breast cancer Prognosis Cox Multiple factors analysis
  • 相关文献

参考文献2

  • 1蒋树娟,仲兰荪,魏英,杜心垿.CD44在乳腺癌中的表达与预后的关系[J].中国癌症杂志,1999,9(4):281-283. 被引量:1
  • 2Yau-Tong You,Chung-Rong Changchien,Jen-Seng Huang,Koon-Kwan Ng. Combining systemic chemotherapy with chemoembolization in the treatment of unresectable hepatic metastases from colorectal cancer[J] 2006,International Journal of Colorectal Disease(1):33~37

二级参考文献2

同被引文献17

  • 1夏学巍,苏长保.PPARγ受体激动剂抗肿瘤作用机制研究进展[J].基础医学与临床,2005,25(12):1109-1113. 被引量:11
  • 2卢崇亮.转移性乳腺癌的治疗进展[J].中国现代普通外科进展,2006,9(1):10-13. 被引量:4
  • 3张慧灵,顾振纶,秦正红.PPARs与神经退行性疾病[J].中国药理学通报,2006,22(4):397-402. 被引量:13
  • 4秦继勇,李娅,蒋美萍,鞠云鹤.81例乳腺癌首发骨转移的综合治疗分析[J].中国肿瘤,2007,16(7):572-574. 被引量:3
  • 5Solomayer EF,Diel IJ,Meyberg GC,et al.Metastatic breast cancer:clinical course,prognosis and therapy related to the first site of metastasis[J].Breast Cancer Res Treat,2000,59:271-278.
  • 6Colleoni M,O'Neill A,Goldhirsch A,et al.Identifying breast cancer patients at high risk for bone metastases[J].J Clin Oncol,2000,18(23):3925-3935.
  • 7Mitsuru K,Masataka Y,Fujio K,et al.What do breast cancer patients benefit from staging bone scintigraphy[J].Jpn J Clin oncol,2001,31(6):263-269.
  • 8Gelman L, Fruchart JC, Auwerx J. An update on the mechanisms of ac-tion of the peroxisome proliferators-activated receptors (PPARs) and their roles in inflammation and cancer [J]. CenMol Life Sci, 1999, 55: 932-43.
  • 9Moraes LA, Piqueras L, Bishop-Bailey D. Peroxisome proliferatoractivated receptors and inflammation [.J]. Pharmacol Ther, 2006, 110: 371-385.
  • 10Shankaranarayanan P, Rossin A, Khanwalkar H, et al. Growth factor -antagonized rexinoid apoptosis involves permissive PPARgamma/RXR heterodimers to activate the intrinsic death pathway by NO [J]. Cancer Cell, 2009, 16 (3) .

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部